Lincoln Pharma zooms on the BSE

Lincoln Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 531633 | NSE: LINCOLN

13 Jan 2012 Evaluate

Lincoln Pharmaceuticals is currently trading at Rs 29.95, up by 1.55 points or 5.46% from its previous closing of Rs 28.40 on the BSE.

The scrip opened at Rs. 29.95 and has touched a high and low of Rs 29.95 and Rs 29.95 respectively.

The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 47.00 on 20-Jan-2011 and a 52 week low of Rs 19.25 on 16-Dec-2011.

Last one week high and low of the scrip stood at Rs 31.90 and Rs 24.30 respectively. The current market cap of the company is Rs 48.85 crore.

The promoters holding in the company stood at 24.54% while Non-Institutions held 75.46% stake in the company.

Lincoln Pharmaceuticals (LPL), a world class pharmaceutical company has entered into an agreement with Switzerland-based Phafag AG, for its Caroverine molecule for the treatment of Tinnitus-commonly known as “ringing in the ear”, a condition where inner hair cells get damaged causing continuous depression, anxiety and insomnia in patients. Millions of people around the world suffer from Tinnitus. It becomes the first company in India to introduce a cure for Tinnitus as Tinnex injection using Caroverine.

With a large number of people suffering from Tinnitus and not much is being done about it, the company invested in the R&D and took the first steps towards bringing the patients suffering from Tinnitus closer to treatment. The company developed Caroverine injection under research and development collaboration with Phafag AG to introduce Tinnex.

Tinnex Injection is a slow intravenous infusion. The dosage differs from patient to patient and depends on the severity.

Lincoln Pharmaceuticals has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters.

Lincoln Pharma Share Price

611.05 -20.20 (-3.20%)

18-Jun-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1824.00
Dr. Reddys Lab	1267.80
Cipla	1355.80
Zydus Lifesciences	1074.30
Lupin	2327.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.